Efficacy of Oral Ibandronate in Osteoporosis

Examination of Bone Metabolism and Bone Mineral Density in Primary and Secondary Osteoporosis Treated by Oral Ibandronate

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03186131

Enrollment

100

Registered

2017-06-14

Start date

2017-10-12

Completion date

2025-06-08

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

There has been no comparative data between oral ibandronate and oral ibandronate plus active vitamin D

Interventions

DRUGIbandronate

To examine the efficacy of oral Ibandronate in osteoporosis

DRUGOral Ibandronate and Vitamin D

To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Osteoporotic patients who want to take oral ibandronate

Exclusion criteria

* Patients who are allergic to oral ibandronate or vitamin D Patients who have not taken oral ibandronate for the last 2 years

Design outcomes

Primary

Measure	Time frame
Bone mineral density	Change from Baseline Values at 1 year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026